Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives
Authors
Keywords
-
Journal
Targeted Oncology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-03-09
DOI
10.1007/s11523-021-00802-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines
- (2020) Stephen J Schuster et al. BLOOD
- Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma
- (2020) Georg Lenz et al. LEUKEMIA
- Epcoritamab (GEN3013; DuoBody-CD3×CD20) to induce complete response in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL): Complete dose escalation data and efficacy results from a phase I/II trial.
- (2020) Martin Hutchings et al. JOURNAL OF CLINICAL ONCOLOGY
- Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL).
- (2020) Caron A. Jacobson et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor infiltrating T cells influence prognosis in stage I–III non-small cell lung cancer
- (2020) Arik Bernard Schulze et al. Journal of Thoracic Disease
- Copanlisib in the treatment of non-Hodgkin lymphoma
- (2020) Mayur Narkhede et al. Future Oncology
- How I treat early relapsing follicular lymphoma
- (2019) Carla Casulo et al. BLOOD
- Insulin-Driven PI3K-AKT Signaling in the Hepatocyte Is Mediated by Redundant PI3Kα and PI3Kβ Activities and Is Promoted by RAS
- (2019) Angela Molinaro et al. Cell Metabolism
- High Rate of Durable Complete Remission in Follicular Lymphoma after CD19 CAR-T cell Immunotherapy
- (2019) Alexandre V. Hirayama et al. BLOOD
- Diagnosis and management of follicular lymphoma: A comprehensive review
- (2019) Reyad Dada EUROPEAN JOURNAL OF HAEMATOLOGY
- Maximizing the effectiveness of oral therapies in lymphoid cancers: research gaps and unmet needs
- (2019) Alix Y. L. Zackon et al. LEUKEMIA & LYMPHOMA
- Combination trial of duvelisib (IPI‐145) with rituximab or bendamustine/rituximab in patients with non‐Hodgkin lymphoma or chronic lymphocytic leukemia
- (2019) Ian W. Flinn et al. AMERICAN JOURNAL OF HEMATOLOGY
- On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors
- (2019) Franck Morschhauser et al. MOLECULAR CANCER THERAPEUTICS
- Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study
- (2018) Ian W. Flinn et al. AMERICAN JOURNAL OF HEMATOLOGY
- The PI3K/AKT pathway in obesity and type 2 diabetes
- (2018) Xingjun Huang et al. International Journal of Biological Sciences
- Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date
- (2018) Felix Mensah et al. OncoTargets and Therapy
- Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen
- (2018) Nirav N. Shah et al. Clinical Lymphoma Myeloma & Leukemia
- The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer
- (2017) Kai Wang et al. HUMAN PATHOLOGY
- Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma
- (2017) Martin Dreyling et al. JOURNAL OF CLINICAL ONCOLOGY
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors
- (2017) Dejan Juric et al. Cancer Discovery
- A first-in-human phase I study of intravenous PI3K inhibitor BAY 80-6946 in patients with advanced solid tumors: Results of dose-escalation phase.
- (2017) A. Patnaik et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
- (2016) A. Patnaik et al. ANNALS OF ONCOLOGY
- Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy
- (2016) V. Jurinovic et al. BLOOD
- A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER + /HER2 − Metastatic Breast Cancer
- (2016) Ingrid A. Mayer et al. CLINICAL CANCER RESEARCH
- Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management
- (2016) Khurum H. Khan et al. ONCOLOGIST
- Idelalisib-associated Colitis
- (2015) Anna-Sophie Weidner et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer
- (2015) G. I. Shapiro et al. CLINICAL CANCER RESEARCH
- Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study
- (2015) Carla Casulo et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of adverse events associated with idelalisib treatment: expert panel opinion
- (2015) Steven E. Coutré et al. LEUKEMIA & LYMPHOMA
- Constitutive AKT activation in follicular lymphoma
- (2014) Ouardia I Yahiaoui et al. BMC CANCER
- Impact of the healthcare payment system on patient access to oral anticancer drugs: an illustration from the French and United States contexts
- (2014) Laure Benjamin et al. BMC HEALTH SERVICES RESEARCH
- Tumour-infiltrating CD4+ and CD8+ lymphocytes as predictors of clinical outcome in glioma
- (2014) S Han et al. BRITISH JOURNAL OF CANCER
- First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors
- (2014) D. Sarker et al. CLINICAL CANCER RESEARCH
- Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab
- (2013) Zi-Zhen Xu et al. ANNALS OF HEMATOLOGY
- BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models
- (2013) Ningshu Liu et al. MOLECULAR CANCER THERAPEUTICS
- Management of indolent lymphoma: Where are we now and where are we going
- (2012) Matthew A. Lunning et al. BLOOD REVIEWS
- Pathogenesis of Non-Hodgkin's Lymphoma
- (2011) Hendrik Nogai et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
- (2011) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- Regulation of arterial blood pressure by Akt1-dependent vascular relaxation
- (2011) Jung Min Ha et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Targeting the PI3K/AKT/mTOR Pathway in Non-Hodgkin’s Lymphoma: Results, Biology, and Development Strategies
- (2011) Jonathan H. Schatz Current Oncology Reports
- Insulin says NO to cardiovascular disease
- (2010) Q. Yu et al. CARDIOVASCULAR RESEARCH
- Specific Roles of the p110α Isoform of Phosphatidylinsositol 3-Kinase in Hepatic Insulin Signaling and Metabolic Regulation
- (2010) Victoria Rotter Sopasakis et al. Cell Metabolism
- Aggressive Lymphomas
- (2010) Georg Lenz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Contribution of Insulin and Akt1 Signaling to Endothelial Nitric Oxide Synthase in the Regulation of Endothelial Function and Blood Pressure
- (2009) J. David Symons et al. CIRCULATION RESEARCH
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- Stromal Gene Signatures in Large-B-Cell Lymphomas
- (2008) G. Lenz et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started